Novavax enters late-stage clinical trials for COVID-19
In this file photo three potential coronavirus, COVID-19, vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19. US biotech firm Novavax said Ton September 24, 2020 it was initiating its final Phase 3 clinical trial for its experimental Covid-19 vaccine. The trial will be carried out in the United Kingdom and aims to enroll 10,000 volunteers, aged 18-84, with and without underlying conditions, over the next four to six weeks.
AFP/Andrew Caballero-Reynolds
Novavax enters late-stage clinical trials for COVID-19
(Agence France-Presse) - September 25, 2020 - 11:35am

WASHINGTON, United States — US biotech firm Novavax said Thursday it was initiating its final Phase 3 clinical trial for its experimental COVID-19 vaccine.

The trial will be carried out in the United Kingdom and aims to enroll 10,000 volunteers, aged 18-84, with and without underlying conditions, over the next four to six weeks.

"With a high level of SARS-CoV-2 transmission observed and expected to continue in the  UK, we are optimistic that this pivotal Phase 3 clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373's efficacy," said Gregory Glenn, the company's president of research and development, using the technical name for the formulation.

It is the eleventh COVID-19 vaccine candidate to reach the Phase 3 stage globally.

The company has been awarded $1.6 billion by the US government to develop and fund the drug, which is administered by two intramuscular injections.

The Maryland-based company uses insect cells to grow synthesized pieces of the spike protein of the virus, which it hopes will evoke a robust human immune response.

It also uses an "adjuvant," a compound that boosts the production of neutralizing antibodies.

The company says the drug, which is a liquid formulation, can be stored at two degrees celsius to eight degrees celsius, refrigerator temperature.

In the spring, the company said it had proven the efficacy of a seasonal flu vaccine it had developed using the same technology.

2019 N-COV COVID-19 VACCINE NOVEL CORONAVIRUS
Philstar
  • Latest
  • Trending
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with